tiprankstipranks
Nevro reports Q1 EPS (98c), consensus ($1.04)
The Fly

Nevro reports Q1 EPS (98c), consensus ($1.04)

Reports Q1 revenue $96.3M, consensus $95.18M. "We continued to move our business forward in the first quarter, as evidenced by trial activity that improved throughout the quarter, as well as ongoing improvement in permanent implant volumes," said D. Keith Grossman, Executive Chairman. "I’m very pleased with the progress that we’ve made over the last few years, and believe that the company is stronger and better positioned for attractive growth and leverage going forward, particularly as the core SCS market returns to growth throughout this year and next." "Our PDN progress with referring clinicians, payers and clinical societies continues to move at a brisk pace, and we are looking forward to further developing this exciting growth platform," stated Kevin Thornal, CEO. "We also initiated the full market launch of our new HFX iQ system, the first powered by artificial intelligence and the only SCS system that gets smarter over time by learning from patient responses. My top priority will be to build on the progress the company has made, driving growth and taking advantage of the meaningful leverage opportunities we have to drive toward profitability and deliver shareholder value."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NVRO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles